Specifications
- Purity
- ≥99%
- Appearance
- Off-white powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO (20 mg/ml) or water (30 mg/ml).
Available from stock
LY2835219
- SKU
- L0303
Category: API's & Intermediates
- Synonyms
- LY2835219 methanesulfonate , Abemaciclib methanesulfonate , Abemaciclib mesylate , Bemaciclib
- 1231930-82-7
- CAS-Number
- C27H32F2N8.CH4O3S
- Molecular Formula
- 602.7
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- RT
- Long Term Storage
- RT
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at RT.
- Hazard statements
- H315, H319, H335
- Precautionary statements
- P261, P305+351+338, P302+352
- GHS Symbol
- GHS07
- Signal word
- Warning
- Transportation
- Not dangerous goods
- Description
- LY2835219 is an orally-bioavailable dual inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6 (IC50s = 2 and 10 nM, respectively). Through this mechanism, it blocks phosphorylation of retinoblastoma protein, resulting in arrest of cell cycling in the G1 phase. LY2835219 has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds.
- Smiles
- CCN(CC1)CCN1CC2=CC=C(NC3=NC=C(F)C(C4=CC(F)=C(N=C(C)N5C(C)C)C5=C4)=N3)N=C2.CS(=O)(O)=O
- InChi Key
- NCJPFQPEVDHJAZ-UHFFFAOYSA-N
- References
- (1) M.A. Dickson, Clin. Cancer Res. 20, 3379 (2014) , (2) L.M. Gelbert, et al., Invest. New. Drugs 32, 825 (2014) , (3) S.C. Tate, et al., Clin. Cancer Res. 20, 3763 (2014)
- InChi
- InChI=1S/C27H32F2N8.CH4O3S/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26;1-5(2,3)4/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34);1H3,(H,2,3,4)
LY2835219 is an orally-bioavailable dual inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6 (IC50s = 2 and 10 nM, respectively). Through this mechanism, it blocks phosphorylation of retinoblastoma protein, resulting in arrest of cell cycling in the G1 phase. LY2835219 has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds.
Additional information
| Synonyms | LY2835219 methanesulfonate, Abemaciclib methanesulfonate, Abemaciclib mesylate, Bemaciclib |
|---|---|
| Purity | ≥99% |
| Appearance | Off-white powder |
| CAS-Number | 1231930-82-7 |
| Molecular Formula | C27H32F2N8.CH4O3S |
| Molecular Weight | 602.7 |
| Identity | 1H-NMR |
| Solvents | DMSO (20 mg/ml) or water (30 mg/ml). |
| Smiles | CCN(CC1)CCN1CC2=CC=C(NC3=NC=C(F)C(C4=CC(F)=C(N=C(C)N5C(C)C)C5=C4)=N3)N=C2.CS(=O)(O)=O |
| InChi Key | NCJPFQPEVDHJAZ-UHFFFAOYSA-N |
| Shipping | AMBIENT |
| Short Term Storage | RT |
| Long Term Storage | RT |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at RT. |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | P261, P305+351+338, P302+352 |
| GHS Symbol | GHS07 |
| Signal word | Warning |
| Transportation | Not dangerous goods |
| References | (1) M.A. Dickson, Clin. Cancer Res. 20, 3379 (2014), (2) L.M. Gelbert, et al., Invest. New. Drugs 32, 825 (2014), (3) S.C. Tate, et al., Clin. Cancer Res. 20, 3763 (2014) |
| InChi | InChI=1S/C27H32F2N8.CH4O3S/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26;1-5(2,3)4/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34);1H3,(H,2,3,4) |
| Quantity | 100 mg, 250 mg, Bulk |
